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Abstract
Background: TLN-4601 is a structurally novel farnesylated dibenzodiazepinone discovered using Thallion’s
proprietary DECIPHER® technology, a genomics and bioinformatics platform that predicts the chemical structures of
secondary metabolites based on gene sequences obtained by scanning bacterial genomes. Our recent studies
suggest that TLN-4601 inhibits the Ras-ERK MAPK pathway post Ras prenylation and prior to MEK activation. The
Ras-ERK MAPK signaling pathway is a well-validated oncogenic cascade based on its central role in regulating the
growth and survival of cells from a broad spectrum of human tumors. Furthermore, RAS isoforms are the most
frequently mutated oncogenes, occurring in approximately 30% of all human cancers, and KRAS is the most
commonly mutated RAS gene, with a greater than 90% incidence of mutation in pancreatic cancer.
Results: To evaluate whether TLN-4601 interferes with K-Ras signaling, we utilized human pancreatic epithelial cells
and demonstrate that TLN-4601 treatment resulted in a dose- and time-dependent inhibition of Ras-ERK MAPK
signaling. The compound also reduced Ras-GTP levels and induced apoptosis. Finally, treatment of MIA PaCa-2
tumor-bearing mice with TLN-4601 resulted in antitumor activity and decreased tumor Raf-1 protein levels.
Conclusion: These data, together with phase I/II clinical data showing tolerability of TLN-4601, support conducting
a clinical trial in advanced pancreatic cancer patients.
Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer death in North America and has
a five-year survival rate of less than 5% [1]. Most
patients with pancreatic cancer will die within six
months of initial diagnosis. This poor prognosis has
been related to the difficulty of detection in early stages
of development, resulting in advanced disease at the
time of presentation of first symptoms.
To acquire malignancy, pancreatic ductal epithelial
cells undergo a series of sequential genetic mutations.
Among the initial events are KRAS mutations and
HER-2/neu amplification, followed by the loss of
p16INK4A/CDKN2 expression and then inactivation of
p53 and DPC4/SMAD4 [2-4]. KRAS mutations occur in
almost all cases of pancreatic cancer. The most common
alterations are substitutions at the codon 12 glycine,
producing constitutively active K-Ras [4-6]. K-Ras is a
small GTPase that is a key player in various signaling
pathways, working as a molecular switch to transmit sig-
nals from the cell membrane to the cytoplasm and
nucleus [7,8]. A variety of extracellular signals (hor-
mones and growth factors) activate Ras by causing the
exchange of GDP with GTP. In one of the canonical sig-
naling pathways, K-Ras recruits Raf kinases (Raf-1,
B-Raf, or A-Raf) to the cell membrane where their own
activation takes place. Once activated, Raf phosphory-
lates mitogen-activated protein kinases (MEK1/2), which
in turn phosphorylate and activate extracellular signal-
regulated kinases (ERK1/2) [9].
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issue. Since the approval of gemcitabine a decade ago
following only modest increases in efficacy over 5-fluor-
ouracil [10], none of the phase III clinical trials of newer
cytotoxic or biologic agents combined with gemcitabine
showed significant improvements in clinical benefit and
survival (reviewed in [11]). A recent phase III trial com-
bining erlotinib, an oral HER1/EGFR tyrosine kinase
inhibitor, with gemcitabine is the first to demonstrate
statistically significant improved survival in advanced
pancreatic cancer [12]. This regimen is now considered
to be a standard of care for pancreatic cancer, although
the results of the erlotinib trial, while significant,
resulted in only modest efficacy. The median survival
on the combination was 6.24 months versus 5.91
months on gemcitabine alone, and the 1-year survival
rates were 23% with the combination versus 17% with
gemcitabine alone [12]. Therefore, while erlotinib in
combination with gemcitabine is a step forward, there is
still an urgent need to develop more effective drugs.
Recently, a median survival of 11.1 months was
achieved increasing the 1-year survival rate to 48% in a
randomized phase III study on 342 patients receiving
Folfirinox chemotherapy [13]. While gemcitabine has
been the cornerstone for treatment of metastatic pan-
creatic adenocarcinoma, new and promising therapies
are arising.
TLN-4601 (MW 462; US Patent 7,101,872) is a sec-
ondary metabolite produced by Micromonospora sp.
This drug has been discovered through Thallion’s DECI-
PHER® platform, a genome scanning technique that
allows prediction of the production and structure of sec-
ondary metabolites as well as facilitating their isolation
[14-17]. Although the precise mechanism of action of
TLN-4601 is unknown, our earlier work [18] indicated
that TLN-4601 inhibits the EGF-induced Ras-ERK
MAPK signaling pathway post Ras prenylation and prior
to MEK activation and is mechanistically different from
current Raf inhibitors and Ras-signaling inhibitors. The
inhibition of growth factor-induced Ras-ERK MAPK sig-
naling in human breast (MCF7) cells was not through
direct kinase inhibition but rather through a proteaso-
mal-dependent Raf-1 protein degradation [18]. Interest-
ingly, these recent studies indicated that TLN-4601 does
not bind to the conserved binding pocket domain of
HSP90, suggesting a different mechanism of action to
current HSP90 inhibitors. While it is common in breast
cancer to see activation of Ras driven by aberrant
upstream signaling through EGFR, VEGFR, etc. [19-22],
the predominant cause of GTP-bound K-Ras in PDAC
is a result of the aforementioned gene point mutations
[4,6]. As such, it is important to further investigate
TLN-4601 as a potential anti-tumorigenic agent in a
relevant mutationally-activated K-Ras model. In the
present study, we examined whether TLN-4601 could
also inhibit oncogenic K-Ras-mediated signaling and
tumorigenicity, which incorporates contributions from
effector pathways in addition to Raf, by evaluating its
effect on human PDAC and immortalized pancreatic
ductal epithelial cells. Our results indicate that TLN-
4601 decreases activated K-Ras (K-Ras-GTP) and Raf-1,
which are associated with the inhibition of K-Ras-
induced phosphorylation of MEK kinase. Moreover, we
demonstrate that TLN-4601 induces apoptosis and inhi-
bits the growth of human pancreatic (MIA PaCa-2)
tumor xenografts.
Results
TLN-4601 inhibits contact-dependent and -independent
growth in PDAC and immortalized pancreatic duct-
derived cells
To evaluate the effect of TLN-4601 on growth pheno-
types shown to be increased in pancreatic cancer, we
utilized both PDAC and genetically-engineered pancrea-
tic cells expressing oncogenic K-Ras12D (HPNE-KRAS).
Treatment with TLN-4601 resulted in a dose-dependent
growth reduction of all six PDAC cell lines tested com-
pared to vehicle controls (Figure 1A), regardless of their
KRAS status. Similarly, TLN-4601 inhibited growth of
immortalized human pancreatic duct-derived cells
expressing mutant K-Ras12D protein (Figure 1B). These
results indicate that TLN-4601-mediated inhibition of
cell proliferation is not dependent on its ability to block
oncogenic K-Ras function. Weh a v ep r e v i o u s l yd e m o n -
strated that several PDAC cell lines are capable of
avoiding death upon release from a solid substrate [23],
and have similarly demonstrated that expression of
oncogenic K-Ras12D renders the same ability to immor-
talized pancreatic duct-derived cells [24,25]. Using the
soft agar assay, our data indicate that TLN-4601 inhibits
contact-independent colony formation of both pancrea-
tic tumor cells and genetically-transformed pancreatic
cells in a dose-dependent manner (Figure 2A, B). Thus,
TLN-4601 inhibits at least one property of transformed
cells that is dependent upon the activity of oncogenic
K-Ras, ruling out a nonspecific toxic effect of this
compound.
TLN-4601 inhibits the oncogenic K-Ras-MAPK signaling
pathway in PDAC cells
We have previously illustrated that TLN-4601 inhibits
the EGF-induced Ras-ERK MAPK signaling pathway in
human breast tumor (MCF7) cells [18]. To evaluate the
effect of TLN-4601 on the K-Ras signaling pathway in
pancreatic cells, we used several PDAC cancer cell lines.
Many PDAC cell lines have an activated Ras-ERK
MAPK signaling pathway, indicated by the presence of
phosphorylated MEK [26,27]. TLN-4601 modestly
Campbell et al. Journal of Molecular Signaling 2010, 5:18
http://www.jmolecularsignaling.com/content/5/1/18
Page 2 of 10diminished Raf-1 protein levels in some but not all
PDAC lines tested (Figure 3A). More striking, however,
was the dose-dependent decrease in the activation/phos-
phorylation of MEK1/2 (pMEK1/2) in PDAC lines eval-
uated (Figure 3B). The protein levels of MEK1/2 and
ERK1/2 were not affected by TLN-4601, suggesting that
TLN-4601 acts upstream of both MEK and ERK. These
results extend and confirm our previous findings [18].
We chose to focus on a single PDAC cell line (MIA
PaCa-2) harboring a K-Ras mutation at codon 12 to
further investigate the effects of TLN-4601 on the Ras-
ERK MAPK signaling pathway. In cells either stimulated
by EGF (Figure 4A) or growing in normal (10% serum)
conditions (Figure 4B, C), overnight exposure to TLN-
4601 resulted in a dose-dependent decrease in Raf-1
protein and pMEK1/2 (Figure 4A, C). These results con-
firm that TLN-4601 inhibits EGF-induced as well as
constitutively activated Ras-ERK MAPK signaling in a
rapid and persistent manner. A time course evaluation
done at a fixed concentration of drug (10 μM) illustrates
that these effects are observed as early as 4-6 h after
treatment (Figure 4B), and that reduction of Raf-1 pro-
tein levels precedes the reduction in pMEK1/2. This
suggests that TLN-4601 acts upstream of MEK1/2
activation.
TLN-4601 inhibits Ras activation (Ras-GTP) in pancreatic
cancer cells
To discover whether the disruption of downstream Ras
signaling in pancreatic cells might be in part due to a
loss of Ras activation, a pull-down assay was used to
study the effect of TLN-4601 on Ras-GTP in MIA
PaCa-2 cells. This protocol takes advantage of the fact
that the Ras binding domain (RBD) of Raf-1 binds pre-
ferentially to the activated form of Ras (Ras-GTP)
[28-31]. Ras is already activated in the MIA PaCa-2 cell
line and EGF stimulation had a minor effect on Ras-
GTP levels. TLN-4601 treatment reduced EGF-induced
Ras activation in a dose-dependent fashion (Figure 5A),
while it did not affect total Ras protein expression
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Figure 1 TLN-4601 reduces contact-dependent proliferation in PDAC (A) and Ras-transformed immortalized duct derived cells (B). Cells
were treated for 72 h with vehicle or various concentrations of TLN-4601 prior to the addition of the MTT reagent. Data represent the average of
quadruplicate wells + SD of three independent experiments.
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Page 3 of 10(shown by western blotting of total cell lysates obtained
prior to the pull-down fractionation). A reduction in
Ras-GTP levels following TLN-4601 treatment was also
observed in immortalized pancreatic cells expressing
and dependent on mutant Ras (Figure 5B).
TLN-4601 induces apoptosis in MIA PaCa-2 cells
Activation of the Ras-ERK MAPK signaling pathway is
essential for proliferation, differentiation and survival.
Since TLN-4601 inhibits this pathway, we analyzed the
effect of TLN-4601 on survival and apoptosis in MIA
PaCa-2 cells exposed to increasing drug concentrations.
As determined by MTT assay (Figure 1A), 10 μM TLN-
4601 inhibited cell viability by more than 50%. TLN-
4601 treatment resulted in activation of the initiator cas-
pases 8 and 9 and the executor caspases 3 and 7 (Figure
6). Caspase activation leading to PARP cleavage was
observed with 3 μMa n d1 0μM of TLN-4601, correlat-
ing with the MTT data. These results suggest that TLN-
4601-driven diminishment of cell viability is at least in
part due to the induction of apoptosis.
TLN-4601 inhibits the growth of MIA PaCa-2 cell
xenograft tumors
After showing that TLN-4601 inhibits cell growth and
transformation and induces apoptosis in vitro,w ew e r e
interested in assessing its effect in vivo.M i c eh a r b o r i n g
MIA PaCa-2 tumor fragments were treated with 30 mg/kg
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Figure 2 TLN-4601 reduces contact-independent proliferation in PDAC (A) and Ras-transformed immortalized duct derived cells (B).
Cells were seeded into soft agar containing vehicle or various concentrations of TLN-4601. Bars represent the mean colonies per field, averaged
from five fields per well, triplicate wells + SEM, n = 3 independent experiments. Insets are representative wells.
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Page 4 of 10of TLN-4601 daily from Monday to Friday for 3 consecu-
tive weeks. Control mice were treated with either vehicle
(negative control group) or gemcitabine (a standard treat-
ment for pancreatic cancer). Treatment was started when
the tumor xenograft had reached ~55 mm
3, and the effect
of compounds on tumor growth is shown in Figure 7A.
Whereas the average tumor size increased from 57 to
1349 mm
3 in the control group (representing a 23.7 fold
increase), average tumor size in the TLN-4601 treated
group increased from 51 mm
3 to 769 mm
3, representing a
modest (T/C = 57%) but statistically significant reduction
in tumor growth (43% tumor growth reduction; p =
0.009). While gemcitabine was administered at a dose and
schedule reported to give optimal antitumor efficacy in
some pancreatic tumor models [32], it did not result in
significant antitumor efficacy in the MIA PaCa-2 xenograft
model: the %T/C for that group, calculated at Day 49 (the
time at which control mice were sacrificed due to tumor
burden) was 73%, representing a 27% reduction in tumor
growth (p = 0.73).
In order to correlate antitumor activity with the inhi-
bition of the Ras-ERK MAPK signaling pathway by
TLN-4601 observed in vitro, five additional mice bearing
100-200 mm
3 tumors were treated daily for 5 days with
vehicle or 30 mg/kg TLN-4601. Tumor Raf-1 levels
from TLN-4601-treated and control mice were com-
pared by western blot analysis. As shown in Figure 7B,
TLN-4601 treatment resulted in a decrease of Raf-1
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Figure 3 TLN-4601 inhibits the K-Ras downstream signaling cascade in PDAC cells. Exponentially growing cells were treated with
increasing concentrations of TLN-4601. After overnight exposure, cells were lysed and cellular extracts (30 μg protein) were separated on a 10%
SDS-PAGE gel and transferred to nitrocellulose membranes. (A) Membranes were sequentially probed with Raf-1 and ERK1/2 (p44/42 MAP kinase)
or (B) phospho-MEK1/2 (Ser217/221), MEK1 and vinculin (loading control). Blots are representatives of three independent experiments.
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Figure 4 TLN-4601 reduces K-Ras related signaling in EGF- (A) and serum-stimulated MIA PaCa-2 cells (B,C). Cells, treated with either
escalating doses (A, C) or increasing time (B) of TLN-4601, were harvested and lysed for western blot analysis. GAPDH was used as a loading
control.
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Page 5 of 10protein levels in xenograft tumor tissues (p =0 . 0 2 ) ,
which is similar to the effects observed in vitro.
Discussion
TLN-4601 is a structurally novel farnesylated dibenzo-
diazepine that has demonstrated antitumor efficacy
against human hormone-independent breast and pros-
tate tumor xenografts [33]. Its mechanism of action
appears to be associated primarily with its inhibitory
effect on Ras-ERK MAPK signaling [18]. The Ras-ERK
MAPK signaling pathway regulates a large number of
cellular processes, and a broad spectrum of human
tumor types harbor mutations in this pathway leading to
constitutive activation (reviewed in [34]). Pancreatic can-
cer is among these, with 90% of pancreatic cancers exhi-
biting KRAS mutations [35-37]. The importance of Ras
in the initiation and progression of this disease has been
previously reviewed [38]. Moreover, silencing mutant
KRAS by RNA interference (RNAi) in Capan-2 human
pancreatic cancer cells resulted in decreased in vivo
tumorigenicity [39]. Taken together, these data indicate
a critical role of K-Ras in pancreatic cancer and suggest
that targeting mutant K-Ras specifically might be effec-
tive against pancreatic cancer in vivo.
We have previously reported that TLN-4601 inhibits cell
proliferation and Ras-ERK signaling in EGF-stimulated
human breast tumor cells with wild type K-Ras (MCF7)
[18]. Here, we demonstrate that TLN-4601 suppresses
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independent growth of cell lines derived from malignant
pancreatic tumors that harbor different oncogenic K-Ras
mutations. Using the MIA PaCa-2 cell line as a model for
pancreatic cancer, we showed that TLN-4601 resulted in a
time- and concentration-dependent decrease in total Raf-1
protein levels that was associated with a subsequent inhi-
bition of MEK phosphorylation. Together with our pre-
vious data showing that TLN-4601 inhibited Elk-1
transactivation by constitutively activated, N-terminally
truncated Raf-1 BXB, but not by MEK [18], these observa-
tions indicate that TLN-4601 inhibits Ras-ERK signaling
downstream or at the level of Raf-1 and upstream of MEK.
It is well documented that Raf is a major player in
Ras-driven tumorigenesis. Engineered pancreatic duct-
derived cells immortalized and rendered tumorigenic by
ectopic expression of mutant K-Ras have shown that full
K-Ras-dependent transformation requires Raf-MEK-ERK
signaling [24]. The PI3K and the RalGDS pathways were
also upregulated in these cells, but interestingly, inhibi-
tors of the Raf-MEK-ERK cascade (U0126 and BAY 43-
9006) were able to inhibit cellular transformation in this
cell model system [24]. Increasing evidence indicates
that Ras has several other effectors that contribute to
Ras tumorigenic activities: phosphatidylinositol 3-kinases
(PI3K), leading to AKT activation, RalGEF proteins and
phospholipase Cε [40]. These Ras effectors also interact
preferentially with GTP-bound Ras [41], but while it is
clear that Raf-independent Ras-driven transformation
contributes to tumorigenesis [42], the Ras-Raf-
MEK-ERK cascade is still a very enticing area for cancer
therapeutic development. In the present study, we
demonstrate that TLN-4601 disrupts K-Ras signaling in
transformed pancreatic cells by multiple events. First,
TLN-4601 diminishes activated K-Ras-GTP levels,
potentially blunting several oncogenic Ras effector path-
ways. In addition, TLN-4601 decreases cellular Raf-1
protein levels, inhibiting MEK phosphorylation and
MAPK signaling. While the decrease in Raf-1 protein
levels was not observed in all PDAC lines tested, TLN-
4601 exposure was shown to result in a time- and dose-
dependent decrease in MEK activation/phosphorylation
in the PDAC lines evaluated. There are several effector
pathways downstream of Ras, and the oncogenic or
transformative contributions from the varied effectors
differ from cell line to cell line and tumor to tumor.
Given the complex regulation of MAPK activation and
inactivation, both dependent on and independent of Ras
(and Raf-1), not all cell lines depend solely upon Raf-1
for MAPK phosphorylation. Taken together, our data
suggest that the drug may be acting by binding to and/
or targeting a Ras scaffolding partner for degradation
[43], or that TLN-4601 is capable of targeting Ras when
the GTPase is in association with effector proteins such
as Raf-1. Future experiments will focus on potential
TLN-4601 intermediary targets.
Ras controls several aspect of malignant transforma-
tion, among them cell survival and apoptosis, where Ras
activation suppresses apoptosis. In fact it has been
shown that Ras-Raf-ERK and PI3K/AKT signaling path-
ways prevent apoptosis [44]. It is also well documented
that Raf kinase plays an important pro-survival function
that is completely independent of the MAPK signaling
cascade [45]. Treatment with TLN-4601 decreases pro-
liferation and induces apoptosis in MIA PaCa-2 cells, as
shown by MTT assay, caspase activation, and PARP
cleavage. By inhibiting the MAPK signaling pathway and
inducing Raf-1 degradation, TLN-4601 may be sufficient
to overcome Ras- and Raf-1-dependent pro-survival
functions and drive cells into apoptosis. Interestingly,
the PI3K-AKT signaling cascade appears unaffected by
TLN-4601 treatment (data not shown), suggesting that
specificity of action might somehow be conferred by a
Ras-Raf-1-ERK complex that is independent of a PI3K-
AKT axis. In this regard, it is important to note that the
PI3K-AKT signaling pathway is commonly unlinked
from Ras activation. Our previous analyses of pAKT
levels in a large panel of KRAS mutant PDAC cells lines
found infrequent AKT activation, suggesting that this
effector pathway is not consistently activated by Ras
activation in this tumor type [46]. This is also consistent
with our published studies of Ras transformation of var-
ious epithelial cell types (RIE-1 intestinal and ROSE
ovarian), where pAKT levels were not elevated by Ras
activation [47,48].
We further extended our in vitro studies to an in vivo
human pancreatic MIA PaCa-2 xenograft tumor model.
Subcutaneous TLN-4601 administration resulted in
moderate but statistically significant antitumor activity
with a 43% overall reduction of tumor growth compared
to the vehicle control group. Median tumor volume in
the TLN-4601 cohort was significantly less than that of
the gemcitabine treated group, 769 mm
3 and 991 mm
3,
r e s p e c t i v e l ya tD a y4 9 ,t h et i m ea tw h i c hc o n t r o lm i c e
were sacrificed due to tumor burden. The tumor growth
inhibition was associated with a reduction in tumor Raf-
1 protein levels. Raf-1 levels in tumors obtained from 5
mice treated with TLN-4601 were 50% of those found
in tumors obtained from the vehicle-treated control
group. The moderate antitumor activity can be
explained by the rapid decay of circulating plasma TLN-
4601 levels, as documented in a previous study [33].
Indeed, TLN-4601 is rapidly metabolized, and our PK/
P Dw o r kl e du st oc o n c l u d et h a ta n t i t u m o ra c t i v i t y
appears to be associated with the exposure parameter
AUC and/or sustained drug levels rather than on short
elevated systemic drug concentrations (Cmax). While
TLN-4601 is given by continuous i.v. administration in
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tical in mice. Preclinical antitumor evaluation is thus
not performed at optimal drug concentrations.
In summary, TLN-4601 inhibits mutationally acti-
vated K-Ras-MAPK signaling and results in decreased
in vitro contact-dependent and -independent growth of
pancreatic cells, coupled with activation of apoptotic
cascades. Furthermore, TLN-4601 demonstrated PDAC
cell in vivo tumor xenograft growth inhibition, which
was correlated with a reduction in tumor Raf-1 levels.
These findings, together with phase I/II clinical data
showing good safety and tolerability at drug plasma
concentrations in the μM range [49], support further
clinical development in mutated K-Ras-mediated
cancers.
Methods
Cell culture and cell lines
PDAC cell lines, Capan-1 (mutated KRAS
G12V), CFPAC-
1 (mutated KRAS
G12V), MIA PaCa-2 (mutated
KRAS
G12C), PANC-1 (mutated KRAS
G12D), T3M4 (wild
type KRAS), and BxPC-3 (wild type KRAS), were
obtained from the American Type Culture Collection
(ATCC; Manassas, VA). Cells were grown in Dulbecco’s
modified Eagle (DMEM) medium supplemented with
10% heat-inactivated fetal bovine serum (FBS; WISENT
Inc., QC, Canada) and maintained in a humidified atmo-
sphere at 37°C with 5% CO2. Cell lines were started
from frozen stocks, maintained in culture for 15 to 20
passages and were free of Mycoplasma (routinely tested
by PCR; Sigma-Aldrich).
Normal human immortalized pancreatic duct-derived
cells (HPNE) with mutant K-Ras
G12D expression
(HPNE-KRAS) were obtained as previously reported
[24,50]. These cells were maintained at 5% CO2 in M3:5
growth medium [4 parts high-glucose DMEM (Life
Technologies, Carlsbad, CA) to 1 part M3F (INCELL,
San Antonio, TX) supplemented with 5% FBS.
Cell viability assays
Exponentially growing cells were plated into 96-well
plates (5 × 10
3 in 150 μl/well), and 18 h later treated
with increasing concentrations of TLN-4601 for 72 h.
At the end of the treatment, 20 μl of 5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma-Aldrich) was added to each well and the
plates were incubated for an additional 4 h at 37°C. Fol-
lowing this, the medium was removed and replaced with
200 μl of dimethylsulfoxide (DMSO). Experiments were
done in quadruplicate and repeated two to three times.
The absorbance at 570 nm was measured by plate
reader.
Contact-independent growth analysis was performed
according to previous protocols [24]. Briefly, log phase
growing cells were trypsinized, and triplicates of 3 × 10
3
cells per well were suspended in enriched medium (sup-
plemented with an additional 10% fetal calf serum)
mixed with 1.5% sterile agar and plated onto dense agar
coated six-well plates. One ml of standard medium was
added to the top of the gelled matrix and colonies were
grown for 21 days. Stock solutions of TLN-4601 were
dissolved in DMSO and added to both the agar contain-
ing the cells and the feeding medium. After 21 days in
culture, live colonies were counted in five random
three-dimensional fields per well, stained with MTT,
and photographed.
Cell lysis and western blots
After treatment, cells were washed twice with PBS, lysed
in lysis buffer [50 mM Tris-HCl pH 7.4, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl,
1 mM EDTA, phosphatase inhibitor cocktail set II
(EMD Biosciences, Calbiochem, San Diego, CA) and
protease inhibitor cocktail (Roche, Mannheim, Ger-
many)] and cleared by centrifugation at 14000 × g for
10 min. Total proteins (30 μg) were separated by SDS-
PAGE, transferred onto nitrocellulose or PVDF mem-
branes, blocked in 5% nonfat dry milk in TBST and
probed with anti- Raf-1, anti- MEK1/2, anti-ERK1/2,
anti-PARP (all from Cell Signaling Technology, Beverly
MA), anti-phospho-MEK1/2, anti-phospho-ERK1/2,
anti-vinculin and anti-GAPDH (all from Santa Cruz Bio-
technology, Santa Monica, CA). Primary antibodies were
detected with horseradish peroxidase-conjugated sec-
ondary antibodies and chemiluminescent HRP substrate
(Millipore, Mississauga, ON, Canada).
GTP pull-down assays
MIA PaCa-2 cells were cultured in DMEM medium
supplemented with 10% FBS for 18 h, starved for 9 h in
DMEM 0.1% FBS and then treated for 18 h with
increasing concentrations of TLN-4601. At the end of
the treatment, cells were stimulated with EGF (100 mg/
ml) for 5 min. HPNE-KRAS cells were grown in M3:5
growth medium supplemented with 5% FBS and treated
for 18 hours with increasing concentrations of
TLN-4601. Ras GTP levels were determined by a Ras
activation assay kit (Upstate, Millipore) according to the
manufacturer’s directions, or by previously published
protocols [24,51]. Lysates (1 mg of total cell protein in
each sample) were incubated with 10 μg Raf-1-RBD for
45 min at 4°C and centrifuged for 15 sec at 14000 × g
to pellet the agarose beads. After discarding the super-
natant, agarose beads were washed three times with 500
μl of lysis buffer and the pellets were resuspended in 2×
Laemmli sample buffer containing DTT, boiled for
5 min, and centrifuged at 14000 × g.T h es u p e r n a t a n t
was collected and cellular proteins resolved by 12%
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Ras specific antibody.
Animal studies
The xenograft MIA PaCa-2 pancreatic carcinoma donor
tumor was generated by injecting 2 × 10
7 MIA PaCa-2
cells into the right flanks of female Swiss nude mice
(total of 10 mice). Those tumors were excised and small
fragments (~1 mm
3) were implanted s.c. into the right
flanks of female Swiss nude mice (8-9 weeks old). When
tumor volumes reached 50-60 mm
3,m i c ew e r er a n d o -
mized into groups of 10-15 mice and treated. The study
involved a negative control group (vehicle-treated), a
gemcitabine-treated group (60 mg/kg i.p., once a day,
twice per week for four weeks), and a TLN-4601 treated
group (30 mg/kg s.c., once a day Monday through Fri-
day for 3 consecutive weeks). The study was performed
at OncoDesign, Dijon, France in accordance with the
recommendations of the French Ethics Committee and
under the supervision of authorized investigators.
Tumor growth was followed twice a week by measuring
tumor length (L) and width (W) using a caliper. Mea-
surements were converted to tumor volumes (TV; mm
3)
using the standard formula, TV = (L × W)
2/2. Animals
were sacrificed when tumors in the control group
reached a predetermined endpoint TV of ~1400 mm
3
(Day 49). Compound efficacy was assessed by percen-
tage of treated vs control (%T/C) defined as the (median
treated tumor volume/median control tumor volume ×
100). Tumor growth reduction was calculated by sub-
tracting the % T/C from 100.
Evaluation of Raf-1 tumor levels was performed in a
subset of five mice each from the control and TLN-
4601 treated groups after the first five days of treatment.
Tumor lysates were prepared by sonication in lysis buf-
fer and samples were processed as described above.
Statistical analysis was done by ANOVA or Student’s
t test. Differences were considered to be significant at
p < 0.05.
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